tetano
Editor, Senior Moderator
Am J Transplant. 2011 Aug 10. doi: 10.1111/j.1600-6143.2011.03692.x. [Epub ahead of print]
Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients.
Cordero E, Perez-Ordo?ez A, Aydillo TA, Torre-Cisneros J, Gavalda J, Lara R, Segura C, Len O, Cabral E, Gasch A, Pachon J, Perez-Romero P.
Source
Unit of Infectious Disease, Microbiology and Preventive Medicine, Institute of Biomedicine of Sevilla (IBiS), University Hospital Virgen del Roc?o/CSIC/University of Sevilla, Sevilla, Spain Clinic Unit of Infectious Diseases (JTC, RL) and Service of Cardiology, Maimonides Institute for Biomedical Research (IMIBIC) Reina Sofia University Hospital, University of C?rdoba (UCO), Cordoba, Spain Vall d'Hebron University Hospital, Barcelona, Spain.
Abstract
Concern has been raised regarding the response to vaccination in solid organ transplant recipients (SOTR) undergoing immunosuppressant regimens and the possibility of rejection related to the immune response associated with pandemic influenza H1N1-2009 vaccination. The goal of this study was to assess the immunogenicity, efficacy and safety of the pandemic vaccine in SOTR. We performed a multicenter prospective study in SOTR receiving the pandemic vaccine. Immunological response was determined in serum 5 weeks after vaccination by microneutralization assays, and immunoglobulins were measured by ELISA. Three hundred and forty-six SOTR were included. Preexisting seroprotection was detected in 13.6% of cases and rates of seroconversion and seroprotection after vaccination were 73.1% and 82.9%, respectively. Patients with baseline antibody titers had better geometric mean titers (GMT)-post after pandemic vaccination (339.4 vs. 121.4, p < 0.001). Younger age, liver disease and m-TOR inhibitor therapy were independently associated with lower seroprotection and GMT-post. There were no major adverse effects or rejection episodes. Pandemic vaccine was safe in SOTR and elicited an adequate response, although lower than in healthy individuals. This is the first study describing a decreased response after vaccination in patients receiving mTOR inhibitors who presented lower seroprotection rates and lower GMT-post.
? 2011 The Authors Journal compilation ? 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.
PMID:
21831151
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21831151
Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients.
Cordero E, Perez-Ordo?ez A, Aydillo TA, Torre-Cisneros J, Gavalda J, Lara R, Segura C, Len O, Cabral E, Gasch A, Pachon J, Perez-Romero P.
Source
Unit of Infectious Disease, Microbiology and Preventive Medicine, Institute of Biomedicine of Sevilla (IBiS), University Hospital Virgen del Roc?o/CSIC/University of Sevilla, Sevilla, Spain Clinic Unit of Infectious Diseases (JTC, RL) and Service of Cardiology, Maimonides Institute for Biomedical Research (IMIBIC) Reina Sofia University Hospital, University of C?rdoba (UCO), Cordoba, Spain Vall d'Hebron University Hospital, Barcelona, Spain.
Abstract
Concern has been raised regarding the response to vaccination in solid organ transplant recipients (SOTR) undergoing immunosuppressant regimens and the possibility of rejection related to the immune response associated with pandemic influenza H1N1-2009 vaccination. The goal of this study was to assess the immunogenicity, efficacy and safety of the pandemic vaccine in SOTR. We performed a multicenter prospective study in SOTR receiving the pandemic vaccine. Immunological response was determined in serum 5 weeks after vaccination by microneutralization assays, and immunoglobulins were measured by ELISA. Three hundred and forty-six SOTR were included. Preexisting seroprotection was detected in 13.6% of cases and rates of seroconversion and seroprotection after vaccination were 73.1% and 82.9%, respectively. Patients with baseline antibody titers had better geometric mean titers (GMT)-post after pandemic vaccination (339.4 vs. 121.4, p < 0.001). Younger age, liver disease and m-TOR inhibitor therapy were independently associated with lower seroprotection and GMT-post. There were no major adverse effects or rejection episodes. Pandemic vaccine was safe in SOTR and elicited an adequate response, although lower than in healthy individuals. This is the first study describing a decreased response after vaccination in patients receiving mTOR inhibitors who presented lower seroprotection rates and lower GMT-post.
? 2011 The Authors Journal compilation ? 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.
PMID:
21831151
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21831151